Institutional members access full text with Ovid®

Share this article on:

Open Label Ustekinumab for the treatment of anti-TNFα refractory moderate-to-severe Crohn's disease: Follow up of a cohort of patients at an academic inflammatory bowel disease center: P-4.

Rosen, Melissa; Scherl, Ellen; Bosworth, Brian

Clinical Poster Presentations
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website